2nd Fluid & Imaging Biomarkers & Endpoints in Neuroscience Summit 2024
Tuesday, October 22, 2024 - 8:00 AM
to Thursday, October 24, 2024 - 5:00 PM
8:00 AM - 5:00 PM See all dates and Times
Accelerating More Sensitive, Quantitative & Predictive Serological & Imaging Biomarkers to Transform Clinical Development in the CNS.
With the Donanemab ADCOM hailing fluid biomarkers as a deciding factor in the unanimous decision, improved plasma ptau 217 markers and PET tracers, and α-syn self-seeding assay sensitivity and enhancing NFL utility beyond SOD-1 ALS, 2024 has opened the floodgates for biomarker innovation.
The 2nd Fluid & Imaging Biomarkers & Endpoints in Neuroscience forum unites biomarker discovery scientists, imaging experts, neuroscience clinical program leads, and regulatory leaders to engage in forward-thinking discussions to meaningfully advance biomarker assessments of neurodegenerative and neuroinflammatory disease-modifying therapeutics.
This October, join 90+ biomarker discovery scientists, imaging experts, neuroscience clinical program leaders, and regulatory leaders from renowned organizations like AbbVie, Alector, Biogen, Bristol Myers Squibb, Eli Lilly, Eisai, Pfizer, Takeda, Regeneron, and the Michael J. Fox Foundation and many more at the ultimate unique industry-focused networking opportunity to advance precision medicine in neurodegenerative and neuroinflammatory diseases.
Event Links
Website: https://go.evvnt.com/2542184-0
Tickets: https://go.evvnt.com/2542184-2
Brochure: https://go.evvnt.com/2542184-3
